Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on Creative Medical (CELZ) to $20 from $26 and keeps a Buy rating on the shares. The company’s clinical programs are on track, the analyst tells investors in a research note. The firm cites financial modeling adjustments for the target cut.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELZ: